OKUR

OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc. (OKUR) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
D+
Factor Score 1.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.9
EV / EBITDA 0.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -24.6%
Price Return 12M -5.0%
Catalyst Signal 0.00
Market Cap $124.0M
TTM Revenue N/A
Price / Sales N/A
ROE -55.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B+ (3.7) D+ (1.8) C (2.4) D+ (1.8) C+ (2.6) C (2.5)
2026-11-06 B+ (3.8) B+ (3.7) C (2.4) D (1.4) C+ (2.7) C+ (2.8)
2026-10-30 B+ (3.6) B+ (3.6) C (2.4) D (1.5) C+ (2.7) C+ (2.8)
2026-10-23 B+ (3.6) B+ (3.6) C (2.4) D+ (1.5) C+ (2.6) C+ (2.8)
2026-10-16 B+ (3.6) B+ (3.6) C (2.4) D (1.4) C+ (2.6) C+ (2.7)
Page 1 of 4